Soca's Genesist is working exclusively with LLMs that maintain a zero-retention data policy, ensuring your inputs are never used for training.
A path to Genesist series of models :
GEN-LARGE
GEN-ULTRA
GEN-LITE
Multimodal
Soca's Genesist offers tailored enterprise solutions, using multimodal capabilities to enhance understanding and response through Agents.
Data Extraction
Data Visualization
Graph bar
Line chart
Pie chart
Data Communication
Text
Voice
API
Agents
Email
Messaging
Utilities
Compliance
Soca's Genesist prioritizes privacy and data security, ensuring robust compliance measures for the utmost protection of sensitive information.
We don’t train on your data
Your success is driven by your prompts and ideas, not our AI models. We prioritize your trust, training our models without utilizing your specific data.
We don’t share your prompts
We honor you and your team's unique creativity and ensure that your inputs are kept confidential, never shared with others.
We don’t sell your data
We do not engage in trading your data. Our business model neither involves nor will ever involve exploiting user data.
State-of-the-Art RAG
Where conversation meets comprehension and visualization, powered by RAG (Retrieval-Augmented Generation). Talk to your files. Understand them visually.
RAG workflow from Leonie Monigatti
Imagine analyzing a company's quarterly financial report with GENESIST. Forget sifting through dense tables and charts. Just ask, "Show me the key drivers of revenue growth and visually highlight potential trends for future quarters."
Imagine understanding the complexities of climate change data with GENESIST. Forget tedious spreadsheets and abstract models! Just ask, "Show me the impact of rising sea levels on coastal communities, visually highlighting areas most at risk from future flooding."
Imagine delving into a mountain of complex medical research papers with GENESIST. No more endless PDFs and jargon! Simply ask, "Summarize the latest findings on cancer immunotherapy, visually highlighting potential clinical trials for specific patient profiles."